Tag Archive for: deal

Novo Holdings portfolio company Numab Therapeutics announces Johnson & Johnson (‘J&J’) to acquire its wholly-owned subsidiary Yellow Jersey Therapeutics

Under the agreement terms, J&J will pay $1.25 billion to acquire Yellow Jersey Therapeutics, which holds NM26 rights, and will gain full rights to develop, manufacture and commercialize NM26 globally for the treatment of atopic dermatitis and follow-on indications NM26 is a Phase 2-ready bi-specific antibody from Numab’s pipeline of candidates discovered and engineered using […]

TG Therapeutics and Neuraxpharm Announce Ex-US Commercialization Agreement for BRIUMVI® (ublituximab-xiiy)

Total deal size of approximately ~$650M, including over $150M in upfront and near-term milestones Neuraxpharm’s dedicated neurology focus and established European presence makes them an attractive partner for BRIUMVI’s European launch, targeted within the next six months TG retains strategic flexibility with an option to buy back all rights under this agreement if TG is […]

Synaffix Announces Expansion of ADC Collaboration with MacroGenics

MacroGenics adds up to four ADC programs MacroGenics may combine both its proprietary antibody and bispecific DART® technologies with Synaffix’s linker-payload technologies Expanded collaboration includes up to $2.2 billion in total potential payments plus tiered royalties on net sales  AMSTERDAM, NETHERLANDS, 14 March 2023, Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform […]